CryoPort (NASDAQ:CYRX) Insider Sells $199,300.00 in Stock

Key Points

• Insider Mark Sawicki sold 10,000 CryoPort shares for $199,300, reducing his ownership by 9.77% to 92,356 shares.
• CryoPort reported a quarterly loss of $0.25 per share, missing analyst expectations of a $0.18 loss, while revenue of $50.22 million exceeded forecasts of $48.66 million.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $21.69; shares were trading at $20.10 after falling 2.2% Thursday.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) insider Mark Sawicki sold 10,000 shares of CryoPort stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total value of $199,300.00. Following the completion of the sale, the insider owned 92,356 shares of the company's stock, valued at $1,840,655.08. The trade was a 9.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CryoPort Stock Down 2.2%

NASDAQ:CYRX traded down $0.46 during mid-day trading on Thursday, reaching $20.10. The company's stock had a trading volume of 659,177 shares, compared to its average volume of 664,215. CryoPort, Inc. has a 1 year low of $7.61 and a 1 year high of $21.78. The stock has a fifty day moving average of $17.26 and a 200-day moving average of $13.61. The firm has a market capitalization of $1.02 billion, a PE ratio of -20.72 and a beta of 1.89.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. The business had revenue of $50.22 million for the quarter, compared to analysts' expectations of $48.66 million. On average, analysts expect that CryoPort, Inc. will post -0.88 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on CYRX shares. Guggenheim boosted their price objective on shares of CryoPort from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Roth Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of CryoPort in a research report on Friday, August 7th. Weiss Ratings raised CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research report on Thursday, October 8th. Piper Sandler upgraded CryoPort to a "buy" rating in a report on Tuesday, October 13th. Finally, BTIG Research boosted their price target on CryoPort from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, CryoPort currently has an average rating of "Moderate Buy" and a consensus price target of $21.69.

Hedge Funds Weigh In On CryoPort

Several hedge funds have recently modified their holdings of CYRX. Roubaix Capital LLC boosted its stake in CryoPort by 12.4% in the 3rd quarter. Roubaix Capital LLC now owns 454,926 shares of the company's stock worth $7,916,000 after purchasing an additional 50,148 shares in the last quarter. White Pine Capital LLC purchased a new stake in CryoPort during the 3rd quarter worth approximately $539,000. Royce & Associates LP purchased a new stake in CryoPort during the 3rd quarter worth approximately $7,073,000. Diversified Trust Co increased its stake in CryoPort by 3.4% during the 3rd quarter. Diversified Trust Co now owns 19,769 shares of the company's stock valued at $344,000 after purchasing an additional 657 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in CryoPort by 376.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company's stock valued at $6,943,000 after purchasing an additional 315,343 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company's services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.